The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition

被引:120
作者
Naftolin, F
Taylor, HS
Karas, R
Brinton, E
Newman, I
Clarkson, TB
Mendelsohn, M
Lobo, PA
Judelson, DR
Nachtigall, LE
Heward, CB
Hecht, H
Jaff, MP
Harman, SM
机构
[1] Yale Univ, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
[2] Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA USA
[3] Carl T Hayden VA Med Ctr, Dept Internal Med, Phoenix, AZ USA
[4] Univ Akron, Inst Life Span Dev & Gerontol, Akron, OH 44325 USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Comparat Med, Winston Salem, NC 27103 USA
[6] Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA
[7] Womens Heart Inst, Los Angeles, CA USA
[8] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA
[9] Kronos Grp, Res & Dev, Phoenix, AZ USA
[10] Beth Israel Deaconess Med Ctr, Phillips Ambulatory Care Ctr, New York, NY 10003 USA
[11] Lenox Hill Hosp, New York, NY 10021 USA
[12] Kronos Longev Res Inst, Phoenix, AZ USA
关键词
menopause; estrogen; progestin; randomized clinical trial; WHI; cardiovascular disease;
D O I
10.1016/j.fertnstert.2004.02.095
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The Women's Health Initiative (WHI) randomized controlled trial failed to show cardioprotection by estrogen plus progestin treatment of postmenopausal women. But by design, the WHI population was 10-fold underpowered to show cardioprotection of women starting hormone treatment during the menopausal transition. Thus, observational studies that showed cardioprotection in such women remain the only applicable clinical guide to this issue. Randomized controlled trials are urgently needed to test cardioprotection in women starting treatment during the menopausal transition.
引用
收藏
页码:1498 / 1501
页数:4
相关论文
共 14 条
[1]  
Diano S, 1999, MENOPAUSE, V6, P21
[2]   Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study - A prospective, observational study [J].
Grodstein, F ;
Manson, JE ;
Stampfer, MJ .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (01) :1-8
[3]   Rapid vascular cell responses to estrogen and membrane receptors [J].
Haynes, MP ;
Li, L ;
Russell, KS ;
Bender, JR .
VASCULAR PHARMACOLOGY, 2002, 38 (02) :99-108
[4]   Effects of estrogen plus progestin on health-related quality of life [J].
Hays, J ;
Ockene, JK ;
Brunner, RL ;
Kotchen, JM ;
Manson, JE ;
Patterson, RE ;
Aragaki, AK ;
Shumaker, SA ;
Brzyski, RG ;
LaCroix, AZ ;
Granek, IA ;
Valanis, BG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1839-1854
[5]   Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women [J].
Hu, FB ;
Stampfer, MJ ;
Manson, JE ;
Grodstein, F ;
Colditz, GA ;
Speizer, FE ;
Willett, WC .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (08) :530-537
[6]  
Karas R, 2003, MENOPAUSAL MED, V10, P8
[7]  
Langer RD, 2003, MENOPAUSAL MED, V10, P5
[8]   MANAGEMENT OF OSTEOPOROSIS [J].
LINDSAY, R .
BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1988, 2 (01) :103-124
[9]   Estrogen plus progestin and the risk of coronary heart disease [J].
Manson, JE ;
Hsia, J ;
Johnson, KC ;
Rossouw, JE ;
Assaf, AR ;
Lasser, NL ;
Trevisan, M ;
Black, HR ;
Heckbert, SR ;
Detrano, R ;
Strickland, OL ;
Wong, ND ;
Crouse, JR ;
Stein, E ;
Cushman, M ;
Alving, B ;
Rossouw, JE ;
Pottern, L ;
Ludlam, S ;
McGowan, JA ;
Prentice, R ;
Anderson, G ;
LaCroix, A ;
Patterson, R ;
McTiernan, A ;
Cochrane, B ;
Hunt, J ;
Tinker, L ;
Kooperberg, C ;
McIntosh, M ;
Wang, CY ;
Chen, C ;
Bowen, D ;
Kristal, A ;
Stanford, J ;
Urban, N ;
Weiss, N ;
White, E ;
Shumaker, S ;
Rautaharju, P ;
Prineas, R ;
Naughton, M ;
Stein, E ;
Laskarzewski, P ;
Cummings, S ;
Nevitt, M ;
Dockrell, M ;
Harnack, L ;
Cammarata, F ;
Lindenfelser, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) :523-534
[10]   Estrogen replacement therapy, atherosclerosis, and vascular function [J].
Mikkola, TS ;
Clarkson, TB .
CARDIOVASCULAR RESEARCH, 2002, 53 (03) :605-619